News
News | Workshop on Projects Including Wande Pharmaceutical Group's Academician Expert Workstation and Huperzine A Controlled-Release Tablets Successfully Held
Date:
27 Jun,2024
On June 8, the seminar on projects—including Wande Pharmaceutical Group’s Academician Expert Workstation and its Huperzine A sustained-release tablets—was successfully held in the conference room on the 17th floor of the headquarters. Guests invited to the meeting included Researcher Tang Xican, an academician of the Chinese Academy of Engineering and researcher at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences; Researcher Zhang Haiyan, leader of a research group at the Shanghai Institute of Materia Medica, CAS; Researcher Gan Yong; Dr. Zhu Chunliu from the same research team; as well as Directors Chu Changbiao and Wang Wei from the Department of Neurology at Xuanwu Hospital, Capital Medical University.
Wanbangde Pharmaceutical Group Co., Ltd.'s Academician and Expert Workstation is led by Tang Xican, an academician of the Chinese Academy of Engineering, doctoral supervisor, and researcher at the Shanghai Institute of Materia Medica, CAS. Together, they have assembled a high-caliber talent team and embarked on in-depth collaboration focusing on new indications, innovative formulations, and combination therapies for huperzine A. This partnership has already yielded remarkable achievements, resulting in 10 groundbreaking invention patents granted across China, the U.S., Japan, and the European Union.
This seminar aims to jointly explore clinical research strategies, such as controlled-release huperzine A tablets, as well as the annual plans for academician (expert)-led collaborative projects and the development of new dosage forms.
The seminar began with a welcoming speech by Chairman Zhao Shouming, who warmly welcomed and sincerely thanked the team led by Academician Tang, as well as the delegation of experts from Xuanwu Hospital. He expressed his hope that this seminar would provide crucial decision-making support for future research endeavors. Wanbangde Pharmaceutical Group has long been dedicated to the research and development and production of huperzine A, and looks forward to further integrating research resources from industry, academia, and government in the years ahead. By focusing on key areas, the company aims to achieve breakthroughs in the clinical application of huperzine A, ultimately bringing significant health benefits to more patients.
Following this, Dr. Zhao Guanjia, Director of the company’s R&D Center, presented an overview of the huperzine A controlled-release tablets and outlined their clinical development plan, prompting the attending experts to offer their respective recommendations.
The annual plan for the academician (expert) collaboration project is proposed by the workstation members, with experts providing feedback and recommendations.
The academician team proposed a new formulation development plan for the subsequent stages of Huperzine A's lifecycle, and attendees engaged in a discussion on its feasibility.
The successful convening of this seminar on projects such as the controlled-release shikonine tablets at the Academician and Expert Workstation has set the direction for the product’s clinical trials and future research planning. Wanbangde Pharmaceutical Group will further strengthen collaboration with experts across various fields, working together to tackle and overcome key technological challenges. In doing so, the company will fulfill its due social responsibility as a pharmaceutical enterprise, ensuring that the groundbreaking global innovation—born from this research—continues to thrive and make a lasting impact.
Related Recommendations